Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

(NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide ...

The global peripheral intravenous catheter market is projected to experience robust growth over the next decade, with market size expected to exceed USD 13,006.1 million by 2034, up from USD 6,489.3 ...

AngioDynamics, a medical device company - manufactures port catheters widely used for patients needing regular IV treatments or medications.However, recent reports have raised concerns regarding certa ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...

Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market ...

Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to ...

Why the high price? One explanation is that hospitals mark up products to balance overhead costs and generate revenue.

It has been more than a month since Hurricane Helene left a trail of devastation from the Florida panhandle through Georgia ...

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.